SG11201903800XA - ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF - Google Patents

ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF

Info

Publication number
SG11201903800XA
SG11201903800XA SG11201903800XA SG11201903800XA SG11201903800XA SG 11201903800X A SG11201903800X A SG 11201903800XA SG 11201903800X A SG11201903800X A SG 11201903800XA SG 11201903800X A SG11201903800X A SG 11201903800XA SG 11201903800X A SG11201903800X A SG 11201903800XA
Authority
SG
Singapore
Prior art keywords
cd66c
antibody
antibody binding
binding specifically
antigen
Prior art date
Application number
SG11201903800XA
Inventor
Sangsoon Yoon
Kwon Pyo Hong
Soseul Kim
Gil Yong Ji
Young Hoon Lim
Original Assignee
Dinona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinona filed Critical Dinona
Publication of SG11201903800XA publication Critical patent/SG11201903800XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Abstract

【 】 The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector 5 comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c- related disease.
SG11201903800XA 2016-11-14 2017-11-14 ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF SG11201903800XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160151359 2016-11-14
PCT/KR2017/012891 WO2018088877A2 (en) 2016-11-14 2017-11-14 Antibody binding specifically to cd66c and use thereof

Publications (1)

Publication Number Publication Date
SG11201903800XA true SG11201903800XA (en) 2019-05-30

Family

ID=62110206

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903800XA SG11201903800XA (en) 2016-11-14 2017-11-14 ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF

Country Status (13)

Country Link
US (1) US11220543B2 (en)
EP (1) EP3560957A4 (en)
JP (2) JP2019535319A (en)
KR (1) KR102019032B1 (en)
CN (1) CN110382533B (en)
AU (1) AU2017358359B2 (en)
BR (1) BR112019009771A2 (en)
CA (1) CA3043691C (en)
IL (1) IL266516B (en)
MX (1) MX2019005491A (en)
PH (1) PH12019501050A1 (en)
SG (1) SG11201903800XA (en)
WO (1) WO2018088877A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170128567A (en) 2015-03-23 2017-11-22 바이엘 파마 악티엔게젤샤프트 Anti-CEACAM6 antibodies and uses thereof
KR102373502B1 (en) * 2018-05-14 2022-03-11 주식회사 금호에이치티 Use of prevention and treatment of disease related to myeloid-derived suppressor cell and use thereof
WO2019221574A1 (en) * 2018-05-14 2019-11-21 다이노나(주) Use for preventing and treating myeloid-derived suppressor cell-related diseases
KR20210091152A (en) * 2018-11-14 2021-07-21 바이엘 악티엔게젤샤프트 Pharmaceutical Combination of Anti-CEACAM6 and Anti-PD-1 or Anti-PD-L1 Antibodies for the Treatment of Cancer
KR102027248B1 (en) * 2018-12-14 2019-10-01 건양대학교 산학협력단 Biomarker for detecting breast cancer stem cell(BCSC) and use thereof
CN112521509B (en) * 2020-12-23 2022-07-08 姚雪英 anti-CEACAM 5 humanized antibody, conjugate thereof and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038996B2 (en) 2004-03-27 2011-10-18 University Of Arizona Composition and method for cancer treatment
US8883162B2 (en) * 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US8748356B2 (en) * 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
US8404812B2 (en) 2010-02-26 2013-03-26 Dinona Inc. Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same
KR101214177B1 (en) * 2010-02-26 2012-12-21 다이노나(주) Epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same
KR101919170B1 (en) * 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Neutralizing anti-ccl20 antibodies
SG10201700698WA (en) 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR102362803B1 (en) 2013-11-25 2022-02-14 페임웨이브 리미티드 Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
KR101710936B1 (en) 2014-09-12 2017-02-28 전영권 Solar cells and manufacturing method for the same
KR20170128567A (en) * 2015-03-23 2017-11-22 바이엘 파마 악티엔게젤샤프트 Anti-CEACAM6 antibodies and uses thereof
KR101783907B1 (en) * 2016-03-15 2017-10-10 다이노나(주) composition for preventing or treating lung cancer comprising antibody against CD66c and chemical drug
WO2017209318A1 (en) 2016-05-30 2017-12-07 다이노나(주) Antibody binding to carbonic anhydrases, and use thereof

Also Published As

Publication number Publication date
WO2018088877A2 (en) 2018-05-17
PH12019501050A1 (en) 2019-12-11
JP2019535319A (en) 2019-12-12
WO2018088877A3 (en) 2018-10-04
WO2018088877A9 (en) 2018-11-08
AU2017358359B2 (en) 2021-04-01
CN110382533A (en) 2019-10-25
IL266516B (en) 2021-12-01
JP2021177770A (en) 2021-11-18
CN110382533B (en) 2023-09-22
CA3043691C (en) 2022-11-29
KR20180054492A (en) 2018-05-24
IL266516A (en) 2019-08-29
KR102019032B1 (en) 2019-09-06
US11220543B2 (en) 2022-01-11
CA3043691A1 (en) 2018-05-17
EP3560957A2 (en) 2019-10-30
EP3560957A4 (en) 2020-10-21
US20190263905A1 (en) 2019-08-29
BR112019009771A2 (en) 2019-09-17
MX2019005491A (en) 2019-08-12
JP7450585B2 (en) 2024-03-15
AU2017358359A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
SG11201903800XA (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
MX2020001996A (en) Anti-cd137 molecules and use thereof.
MX2019010972A (en) High affinity mage-a1-specific tcrs and uses thereof.
MX2018003470A (en) Novel anti-mesothelin antibody and composition comprising the same.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
EA201790799A1 (en) COMPOSITIONS AND METHODS FOR USE TO STRENGTHEN IMMUNE RESPONSE AND THERAPY OF MALIGNANT TUMORS
MX2022004072A (en) Factor xi antibodies and methods of use.
MX2019001769A (en) T cell receptors and immune therapy using the same.
MX2017016502A (en) Antibodies to cd40 with enhanced agonist activity.
MX2017016253A (en) Antibodies to cd40.
RU2757308C2 (en) Introduction of constructed t cells for the treatment of central nervous system cancer
PH12019500571A1 (en) Anti-pd-1 antibodies
PH12019500312A1 (en) T cell receptors and immune therapy using the same
EA201291195A1 (en) IMPROVED CANCER TREATMENT BASED ON TUMOR ASSOCIATED ANTIGENS OBTAINED FROM CYCLINE D1
MX2023001540A (en) Cancer vaccines and methods of treatment using the same.
WO2018027124A8 (en) Anti-o2 antibodies and uses thereof
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
PH12019502274A1 (en) Antibodies binding to steap-1
MX2022000242A (en) Antibodies to ticagrelor and methods of use.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TW201613978A (en) Angiopoietin-like 4 antibodies and methods of use
MX2022004086A (en) Anti-tigit antibodies and uses thereof.
MX2021003281A (en) Anti-human cd45rc antibodies and uses thereof.
MX2020001287A (en) Braf-specific tcrs and uses thereof.